Portage Biotech Unveils Promising Preclinical Data for PORT-7 in Mesothelioma, Paving Way for First-In-Human Trial

Stock Information for Portage Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Portage Biotech Inc.

AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem
Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025
Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements
Portage Biotech and Compedica Stock-for-Stock Exchange
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.